Investigational Drug Information for JNJ-42165279
✉ Email this page to a colleague
What is the drug development status for JNJ-42165279?
JNJ-42165279 is an investigational drug.
There have been 9 clinical trials for JNJ-42165279.
The most recent clinical trial was a Phase 2 trial, which was initiated on June 11th 2015.
The most common disease conditions in clinical trials are Disease, Anxiety Disorders, and Phobic Disorders. The leading clinical trial sponsors are Janssen Research & Development, LLC, Janssen-Cilag International NV, and Janssen Pharmaceutica N.V., Belgium.
There is one US patent protecting this investigational drug and twenty-nine international patents.
Summary for JNJ-42165279
| US Patents | 1 |
| International Patents | 29 |
| US Patent Applications | 4 |
| WIPO Patent Applications | 2 |
| Japanese Patent Applications | 1 |
| Clinical Trial Progress | Phase 2 (2015-06-11) |
| Vendors | 44 |
Recent Clinical Trials for JNJ-42165279
| Title | Sponsor | Phase |
|---|---|---|
| A Study to Investigate the Efficacy, Safety, and Tolerability of JNJ-42165279 in Adolescent and Adult Participants With Autism Spectrum Disorder | Janssen Research & Development, LLC | Phase 2 |
| A Single and Multiple Dose Study to Investigate Safety, Tolerability and Pharmacokinetics of JNJ-42165279 in Healthy Japanese Male Participants | Janssen Research & Development, LLC | Phase 1 |
| An Efficacy, Safety and Tolerability Study of JNJ-42165279 in Participants With Major Depressive Disorder With Anxious Distress | Janssen Research & Development, LLC | Phase 2 |
Clinical Trial Summary for JNJ-42165279
Top disease conditions for JNJ-42165279
Top clinical trial sponsors for JNJ-42165279
International Patents for JNJ-42165279
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| JNJ-42165279 | Australia | AU2011248407 | 2030-05-03 | ⤷ Sign Up |
| JNJ-42165279 | Brazil | BR112012028179 | 2030-05-03 | ⤷ Sign Up |
| JNJ-42165279 | Canada | CA2797100 | 2030-05-03 | ⤷ Sign Up |
| JNJ-42165279 | Chile | CL2012003071 | 2030-05-03 | ⤷ Sign Up |
| JNJ-42165279 | China | CN102869658 | 2030-05-03 | ⤷ Sign Up |
| JNJ-42165279 | Cyprus | CY1115248 | 2030-05-03 | ⤷ Sign Up |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
